Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium

Chien Jung Chang, Yao Chang Chen, Yu Hsun Kao, Yung Kuo Lin, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Dabigatran reduces stroke in atrial fibrillation. Pulmonary veins (PVs) and left atrium (LA) play a critical role in the pathophysiology of atrial fibrillation. We investigated the effects of thrombin, blood clot solution, and dabigatran on PVs and LA. Methods and Results: Conventional microelectrodes were used to record the action potentials in isolated PV and LA preparations before and after the administration of thrombin or blood clot solution in control and dabigatran-treated rabbits. Thrombin (0.01, 0.1, and 1 unit/mL), respectively, reduced the PV (n=6) spontaneous beating rates from 1.9±0.2 to 1.7±0.2, 1.6±0.2, and 1.4±0.3 Hz (P=0.046). Blood clot solution (0.5% and 5.0%), respectively, reduced the PV (n=5) spontaneous beating rates from 2.0±0.4 to 1.8±0.4 and 1.3±0.3 Hz (P=0.044). Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5.0%) increased LA diastolic tension and the resting membrane potential with decreased action potential duration and contractility. Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5%) induced delayed afterdepolarization and burst firing in PVs, but not in LA. N G-nitro-L-arginine methyl ester (100 μmol/L) or a protease-activated receptor type 1 blocker (BMS 200261, 1 μmol/L) attenuated the effects of thrombin and blood clot solution in PVs and LA. Dabigatran-treated PVs had slower spontaneous activity (1.1±0.1 Hz; n=10; P=0.0001 versus control). Their electrophysiological characteristics were not changed by thrombin (1 unit/mL) and blood clot solution (5%). Conclusions: Thrombin modulates PV and LA electric and mechanical characteristics, which were blocked by dabigatran.

Original languageEnglish
Pages (from-to)1176-1183
Number of pages8
JournalCirculation: Arrhythmia and Electrophysiology
Volume5
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Pulmonary Veins
Heart Atria
Thrombin
Thrombosis
Atrial Fibrillation
Action Potentials
PAR-1 Receptor
Dabigatran
NG-Nitroarginine Methyl Ester
Microelectrodes
Membrane Potentials
Stroke
Rabbits

Keywords

  • Atrial fibrillation
  • Direct thrombin inhibitor
  • Protease-activated receptor
  • Pulmonary vein
  • Thrombin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium. / Chang, Chien Jung; Chen, Yao Chang; Kao, Yu Hsun; Lin, Yung Kuo; Chen, Shih Ann; Chen, Yi Jen.

In: Circulation: Arrhythmia and Electrophysiology, Vol. 5, No. 6, 12.2012, p. 1176-1183.

Research output: Contribution to journalArticle

@article{e7c648225ddb48f8a2b0d1b0e79fb695,
title = "Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium",
abstract = "Background: Dabigatran reduces stroke in atrial fibrillation. Pulmonary veins (PVs) and left atrium (LA) play a critical role in the pathophysiology of atrial fibrillation. We investigated the effects of thrombin, blood clot solution, and dabigatran on PVs and LA. Methods and Results: Conventional microelectrodes were used to record the action potentials in isolated PV and LA preparations before and after the administration of thrombin or blood clot solution in control and dabigatran-treated rabbits. Thrombin (0.01, 0.1, and 1 unit/mL), respectively, reduced the PV (n=6) spontaneous beating rates from 1.9±0.2 to 1.7±0.2, 1.6±0.2, and 1.4±0.3 Hz (P=0.046). Blood clot solution (0.5{\%} and 5.0{\%}), respectively, reduced the PV (n=5) spontaneous beating rates from 2.0±0.4 to 1.8±0.4 and 1.3±0.3 Hz (P=0.044). Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5{\%} and 5.0{\%}) increased LA diastolic tension and the resting membrane potential with decreased action potential duration and contractility. Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5{\%} and 5{\%}) induced delayed afterdepolarization and burst firing in PVs, but not in LA. N G-nitro-L-arginine methyl ester (100 μmol/L) or a protease-activated receptor type 1 blocker (BMS 200261, 1 μmol/L) attenuated the effects of thrombin and blood clot solution in PVs and LA. Dabigatran-treated PVs had slower spontaneous activity (1.1±0.1 Hz; n=10; P=0.0001 versus control). Their electrophysiological characteristics were not changed by thrombin (1 unit/mL) and blood clot solution (5{\%}). Conclusions: Thrombin modulates PV and LA electric and mechanical characteristics, which were blocked by dabigatran.",
keywords = "Atrial fibrillation, Direct thrombin inhibitor, Protease-activated receptor, Pulmonary vein, Thrombin",
author = "Chang, {Chien Jung} and Chen, {Yao Chang} and Kao, {Yu Hsun} and Lin, {Yung Kuo} and Chen, {Shih Ann} and Chen, {Yi Jen}",
year = "2012",
month = "12",
doi = "10.1161/CIRCEP.112.971556",
language = "English",
volume = "5",
pages = "1176--1183",
journal = "Circulation: Arrhythmia and Electrophysiology",
issn = "1941-3149",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium

AU - Chang, Chien Jung

AU - Chen, Yao Chang

AU - Kao, Yu Hsun

AU - Lin, Yung Kuo

AU - Chen, Shih Ann

AU - Chen, Yi Jen

PY - 2012/12

Y1 - 2012/12

N2 - Background: Dabigatran reduces stroke in atrial fibrillation. Pulmonary veins (PVs) and left atrium (LA) play a critical role in the pathophysiology of atrial fibrillation. We investigated the effects of thrombin, blood clot solution, and dabigatran on PVs and LA. Methods and Results: Conventional microelectrodes were used to record the action potentials in isolated PV and LA preparations before and after the administration of thrombin or blood clot solution in control and dabigatran-treated rabbits. Thrombin (0.01, 0.1, and 1 unit/mL), respectively, reduced the PV (n=6) spontaneous beating rates from 1.9±0.2 to 1.7±0.2, 1.6±0.2, and 1.4±0.3 Hz (P=0.046). Blood clot solution (0.5% and 5.0%), respectively, reduced the PV (n=5) spontaneous beating rates from 2.0±0.4 to 1.8±0.4 and 1.3±0.3 Hz (P=0.044). Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5.0%) increased LA diastolic tension and the resting membrane potential with decreased action potential duration and contractility. Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5%) induced delayed afterdepolarization and burst firing in PVs, but not in LA. N G-nitro-L-arginine methyl ester (100 μmol/L) or a protease-activated receptor type 1 blocker (BMS 200261, 1 μmol/L) attenuated the effects of thrombin and blood clot solution in PVs and LA. Dabigatran-treated PVs had slower spontaneous activity (1.1±0.1 Hz; n=10; P=0.0001 versus control). Their electrophysiological characteristics were not changed by thrombin (1 unit/mL) and blood clot solution (5%). Conclusions: Thrombin modulates PV and LA electric and mechanical characteristics, which were blocked by dabigatran.

AB - Background: Dabigatran reduces stroke in atrial fibrillation. Pulmonary veins (PVs) and left atrium (LA) play a critical role in the pathophysiology of atrial fibrillation. We investigated the effects of thrombin, blood clot solution, and dabigatran on PVs and LA. Methods and Results: Conventional microelectrodes were used to record the action potentials in isolated PV and LA preparations before and after the administration of thrombin or blood clot solution in control and dabigatran-treated rabbits. Thrombin (0.01, 0.1, and 1 unit/mL), respectively, reduced the PV (n=6) spontaneous beating rates from 1.9±0.2 to 1.7±0.2, 1.6±0.2, and 1.4±0.3 Hz (P=0.046). Blood clot solution (0.5% and 5.0%), respectively, reduced the PV (n=5) spontaneous beating rates from 2.0±0.4 to 1.8±0.4 and 1.3±0.3 Hz (P=0.044). Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5.0%) increased LA diastolic tension and the resting membrane potential with decreased action potential duration and contractility. Thrombin (0.01, 0.1, and 1 unit/mL) and blood clot solution (0.5% and 5%) induced delayed afterdepolarization and burst firing in PVs, but not in LA. N G-nitro-L-arginine methyl ester (100 μmol/L) or a protease-activated receptor type 1 blocker (BMS 200261, 1 μmol/L) attenuated the effects of thrombin and blood clot solution in PVs and LA. Dabigatran-treated PVs had slower spontaneous activity (1.1±0.1 Hz; n=10; P=0.0001 versus control). Their electrophysiological characteristics were not changed by thrombin (1 unit/mL) and blood clot solution (5%). Conclusions: Thrombin modulates PV and LA electric and mechanical characteristics, which were blocked by dabigatran.

KW - Atrial fibrillation

KW - Direct thrombin inhibitor

KW - Protease-activated receptor

KW - Pulmonary vein

KW - Thrombin

UR - http://www.scopus.com/inward/record.url?scp=84873878421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873878421&partnerID=8YFLogxK

U2 - 10.1161/CIRCEP.112.971556

DO - 10.1161/CIRCEP.112.971556

M3 - Article

C2 - 23118275

AN - SCOPUS:84873878421

VL - 5

SP - 1176

EP - 1183

JO - Circulation: Arrhythmia and Electrophysiology

JF - Circulation: Arrhythmia and Electrophysiology

SN - 1941-3149

IS - 6

ER -